HLA-DR matching is effective in reducing posttransplant costs in renal allograft recipients on triple therapy.
Taylor
C J
CJ
Nuffield Department of Surgery, Oxford Transplant Centre, England.
Bayne
A M
AM
Welsh
K I
KI
Morris
P J
PJ
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D016572:Cyclosporine / Q000627:therapeutic use; D006084:Graft Rejection; D006684:HLA-DR Antigens / Q000032:analysis / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000191:economics / Q000276:immunology*; D011239:Prednisolone / Q000627:therapeutic use; D012189:Retrospective Studies; D016019:Survival Analysis; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D006684:HLA-DR Antigens; D016572:Cyclosporine; D011239:Prednisolone